查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1853763

癌症惡病質市場按治療類型、通路、給藥途徑、最終用戶和患者人口統計特徵分類－2025-2032年全球預測

Cancer Cachexia Market by Treatment Type, Distribution Channel, Route Of Administration, End User, Patient Demographics - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，癌症惡病質市場規模將成長 41 億美元，複合年成長率為 7.82%。

關鍵市場統計數據
基準年2024年 22.4億美元
預計年份：2025年 24.2億美元
預測年份 2032 41億美元
複合年成長率 (%) 7.82%

為癌症惡病質建構了一個簡潔權威的框架，重點闡述了其臨床複雜性、不斷發展的科學進展以及整合治療和護理策略的必要性。

癌症惡病質仍然是一種複雜的、多因素症候群，它會損害患者康復，使癌症治療更加複雜，並給商業性和臨床相關人員帶來挑戰。早期識別惡病質、整合多學科管理以及使治療策略與以患者為中心的結果一致，是常見的臨床要務。最新的臨床實踐指南強調了營養支持、藥物干預和針對症狀的治療的必要性。

同時，病理學研究揭示了包括全身性發炎、代謝異常和神經激素訊號傳導在內的多種機制。這些進展重新激發了人們對開發能夠調節食慾、抑制分解代謝並干預與肌肉流失相關的訊號通路藥物的興趣。因此，從醫療器材製造商到營養補充劑開發商再到製藥公司，相關人員在重新評估自身在需要跨醫療環境和交付模式的綜合解決方案的生態系統中的角色。

因此，本導言為理解不斷發展的科學、不斷變化的醫療服務模式以及新的商業性需求如何相互作用，從而塑造機會和風險奠定了基礎。在此背景下，接下來的章節將探討不斷變化的市場格局、價格動態變化的影響、可操作的市場區隔和區域洞察，並為希望將洞察說明為實際影響的產業領導者提供明確的建議。

新的科學突破、重新設計的診療路徑以及數位化醫療服務正在融合，重新定義惡病質治療的研發和商業模式。

由於科學、臨床和商業性力量的匯聚，癌症惡病質的治療格局正在改變性變化。基礎科學的進展加深了我們對發炎介質、代謝重編程和食慾調節路徑的理解，從而推動了標靶藥物的研發，並重新激發了人們對合成代謝和食慾刺激藥物的興趣。同時，臨床醫生正在採用更早期的篩檢和評估框架，將臨床路徑從被動的危機管理轉向主動的支持性治療，從而催生了對能夠在早期干預窗口期內使用的產品和服務的需求。

同時，技術賦能的照護模式和遠端醫療正在加速發展，使得在傳統門診就診之外，能夠更頻繁地監測體重、功能狀態和營養攝取量。這些模式有助於收集長期數據並提高患者參與度，從而提升結合藥物治療、營養治療和物理復健的多模式介入措施的可行性。此外，監管機構和支付者越來越認可能夠證明功能獲益和病患報告結果的證據，這提高了臨床研發的標準，同時也為那些能夠顯著改善生活品質的治療方法開闢了新的報銷途徑。

商業動態也在改變。隨著患者和看護者尋求便捷的網路基地台輔助護理產品和補充劑，製造商和服務供應商必須適應通路多元化。同時，製藥公司、營養品公司和醫療器材製造商之間正在建立策略夥伴關係，以提供兼顧生物學因素和輔助需求的綜合解決方案。這種變革性的轉變不僅限於科學和醫療服務，而是遍及整個價值鏈，需要整合臨床證據、分銷能力和支付方參與度的整合策略。

2025年關稅政策的變化正在再形成採購、製造策略和支付方監管，從而改變惡病質相關療法和耗材的商業規劃。

2025年新關稅政策的實施，將進一步增加癌症惡病質相關治療藥物、醫療設備和營養產品的供應鏈和採購計畫的複雜性。跨境貿易成本的增加引發了人們對籌資策略、定價以及分銷網路韌性的擔憂。採購團隊和商業領導者必須權衡投入成本的短期影響與長期決策之間的關係，例如在地化生產、重新談判合約以及在保障淨利率的同時維持病患用藥可及性的庫存策略。

因此，企業正在考慮採用近岸外包和雙重採購策略來降低關稅波動帶來的風險，同時也重新評估與經銷商和批發商的合約條款，以便更公平地分配供應鏈風險。此外，這些變化將影響市場推廣策略，價格敏感型管道可能需要不同的促銷策略和支援模式來維持銷售。對於依賴低溫運輸和特殊包裝的治療藥物而言，關稅負擔的加重將增加現有營運的複雜性，促使企業投資於流程效率和供應鏈透明度。

最後，相關人員應預料到關稅帶來的成本壓力將加速對經濟價值和實際效果證據的需求。不斷上漲的採購成本將迫使醫療支付者和醫療系統更加嚴格地審查有關功能改進和資源消耗降低的說法。因此，那些積極調整採購、生產和價值論證策略的組織，將更有能力在不斷變化的貿易動態環境中保持市場准入和商業性發展勢頭。

多維細分框架將治療方式、分銷管道、給藥途徑、治療環境和患者人口統計特徵結合起來，為制定個人化策略提供依據。

細緻的細分觀點揭示了臨床需求與給藥方式和商業機會的交會點。根據治療類型，相關人員應考慮醫療設備醫療設備和膳食補充劑通常依賴功能獲益和依從性的實際驗證，而藥品則通常需要進行對照試驗來確定其療效和安全性。

分銷管道細分揭示了獲取途徑如何影響藥物的接受度和患者體驗，醫院、線上藥房和零售藥房各自提供不同的用藥支援、諮詢和追蹤服務。通路選擇會影響處方箋發放、處方醫生的認知以及患者支持計畫的設計。給藥途徑細分闡明了注射劑和口服藥物在臨床和操作方面的權衡，並將注射劑進一步細分為靜脈注射和皮下注射。注射劑可能需要醫療機構資源和低溫運輸物流，而口服藥物通常優先考慮門診和居家照護中的用藥依從性支持和便利性。

將終端使用者細分為門診、居家醫療和醫院三大類，凸顯了介入措施必須與護理團隊和工作流程整合的環節。居家照護環境越來越需要簡化的治療方案和強大的遠端監測功能，而醫院介入措施則可以利用多學科團隊和強化支援服務。成人、老年人和兒童群體具有獨特的生理反應和護理考量，男女患者的差異也會影響症狀表現、劑量選擇和支持需求。總而言之，這些細分群體構成了一個多維格局，產品設計、臨床證據產生和商業性策略必須滿足每個治療管道、途徑、使用者和患者的特定需求。

美洲、歐洲、中東和非洲以及亞太地區的區域性考量將推動惡病質治療取得、實證醫學證據產生和供應鏈韌性策略的協調一致。

區域動態對臨床實踐、報銷途徑和供應鏈設計有顯著影響，因此領導者需要將區域模式轉化為可執行的計劃。在美洲，醫療保健系統呈現多樣化的支付模式，並高度重視真實世界證據和結果，以此作為報銷決策的依據。在這種環境下，那些擁有可證實的功能效益和經濟價值分析支持，且能引起整合醫療服務網路和私人支付方共鳴的產品更受青睞。

歐洲、中東和非洲地區法律規範和支付體系的碎片化，使得打入市場策略必須靈活調整，而本地證據的收集和相關人員的參與在市場進入過程中發揮著至關重要的作用。在歐洲部分地區，價格壓力和預算限制促使企業更加關注成本效益和患者獲益；而在中東和非洲部分地區，則存在著透過夥伴關係主導的主導開發和能力夥伴關係來支持治療服務的機會。在整個全部區域範圍內，協調通路夥伴關係、本地生產和採購策略可以提高應對力和可負擔性。

亞太地區多元化的經濟狀況和快速發展的醫療保健投資正在重塑對綜合性惡病質解決方案的需求。該地區部分市場優先採用數位化醫療和居家照護模式，以實現可擴展的遠端監測和患者援助計畫。而在其他地區，由於醫療資源分散且報銷途徑多樣，需要開展重點試點計畫並進行強力的臨床倡導，以證明其價值。在所有地區，監管策略、供應鏈韌性和文化敏感性病人參與的策略性協調將決定哪些產品能夠獲得持續的認可。

製藥、營養品、醫療設備、生物技術和服務供應商之間的競爭與合作動態揭示了通往整合解決方案和夥伴關係主導規模化的路徑。

競爭格局反映了成熟製藥企業、專業醫療器材製造商、營養品公司和新興生技公司等各方力量的融合，它們各自為惡病質生態系統帶來獨特的優勢。製藥公司致力於研發標靶分子，旨在刺激食慾、促進合成代謝和調節發炎反應，並常常在進行對照試驗和與監管機構溝通方面發揮主導。營養品相關企業和膳食補充劑供應商則透過專注於熱量和蛋白質輸送、微量營養素最佳化以及提高患者依從性的技術，為藥物治療提供補充，從而改善整體治療效果。

醫療器材製造商正在提供給藥平台、監測工具和配套技術，以促進對給藥和功能終點的長期評估。新興生物技術公司和臨床階段的研發企業也在引入創新方法來擴展治療套件，並可能與大型公司合作，以擴大研發和商業化規模。這些相關人員之間的策略聯盟十分常見，因為聯合產品可以解決惡病質的多種促進因素​​，並為臨床醫生、相關人員和患者提供更具吸引力的提案主張。

最後，專注於居家輸液、營養諮詢和遠端監測的服務供應商在推廣應用方面發揮著至關重要的作用，他們能夠減少使用障礙並提高患者依從性。這些服務提供者通常是重要的分銷和支援合作夥伴，能夠擴大服務覆蓋範圍並產生真實世界證據以支持臨床價值主張。對於正在評估競爭對手和潛在合作夥伴的機構而言，能夠展現出在證據生成、物流配送和以患者為中心的支持等方面綜合能力的合作夥伴更具優勢。

領導者可採取切實可行的策略重點，協調臨床證據、供應鏈韌性、數位化賦能和跨部門夥伴關係，以加速產生影響力。

產業領導者應進行有針對性的投資，使科學前景與實際應用模式相契合，同時積極降低商業性和營運風險。首先，應優先考慮儘早識別並利用標準化篩檢方案和遠端監測工具納入患者群體，以便儘早展現臨床效益並最佳化治療路徑。同時，應設計包含功能性結果和患者報告結果的臨床項目，並在傳統終點指標的基礎上，納入這些指標，以滿足支付方的期望並支持報銷談判。

第二，我們將建構靈活的供應鏈策略，包括替代採購管道、在適當情況下採用近岸外包，並與通路夥伴攜手合作，在關稅和物流壓力下維持供應。同時，我們將建立夥伴關係，整合藥品、營養品和醫療設備的能力，簡化臨床醫師和支付者的決策流程。第三，我們將投資於數位健康和​​患者援助平台，以提高患者依從性、收集真實世界療效數據並實現基於價值的合約。這些投資也將有助於提高病人參與和改善長期療效。

最後，他們採用在地化的市場推廣策略，根據當地支付方的要求和醫療模式調整證據產生、定價和銷售策略。整合這些方法——臨床相關性、供應鏈韌性、跨部門夥伴關係、數位化和在地化客製化——使機構能夠將科學進步轉化為永續的患者獲益和商業性成功。

一項嚴謹的混合方法研究途徑，結合文獻綜述、相關人員訪談、案例研究和情境分析，為得出可操作的見解提供了支持。

為了全面了解惡病質生態系統，本研究整合了同行評審的臨床文獻、監管舉措、真實世界證據計畫以及與臨床醫生、相關人員和供應鏈專家的訪談。資料收集著重於多資訊來源三角驗證，以檢驗趨勢並確保資料既反映臨床實際情況又兼顧商業性限制。定性資料輔以產品上市、分銷模式和證據產生策略的案例研究，旨在揭示市場准入和規模化發展的實用經驗。

分析方法包括對科學進展進行主題綜合分析、對供應鏈和關稅影響進行情境分析，以及透過細分映射來協調治療方法和管道、途徑、醫療機構和患者群體。相關人員訪談探討了臨床應用的促進因素、報銷預期和營運障礙，而二手文獻則提供了關於疾病機制和治療方法演變的背景資訊。在整個過程中，我們始終強調資訊來源類型的透明度，並明確區分已建立的證據和新興的假設，以指導實際決策。

簡潔扼要的結論強調了整合證據、交付模式和夥伴關係以產生持久影響的臨床緊迫性和策略必要性。

癌症惡病質既是沉重的臨床負擔，也是創新、綜合解決方案的良機，這些方案融合了藥物、營養、器械和服務等要素。科學進步、變革性醫療服務和商業性模式的融合，為相關人員重新思考以功能性結果和病患體驗為優先的治療策略提供了機會。同時，政策變化和價格動態也要求制定周密的營運計劃，以確保患者能夠獲得治療並實現永續的商業化。

總之，成功應對惡病質取決於各機構能否將嚴謹的證據生成與靈活的服務模式結合，能否跨領域建立策略合作，以及能否透過充分展現功能性和經濟價值來贏得支付方的信任。那些能夠有效整合臨床、商業和營運策略的公司，將能夠為患者帶來可衡量的益處，並為投資者和合作夥伴創造永續的利潤。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 整合多模式營養支持和運動通訊協定以改善患者預後
  • Ghrelin肽受體促效劑療法的進展已顯示出改善體重增加的效果
  • 用於早期檢測和進展監測的新興生物標記
  • 遠端醫療平台在遠距監測惡病質治療依從性方面的應用日益廣泛
  • 開發針對代謝途徑的聯合藥物療法以減少肌肉萎縮
  • 增加對個人化醫療方法的投資，以便根據患者表現型客製化惡病質干預措施
  • 整合機器學習演算法以預測惡病質的發生並最佳化治療策略
  • 越來越重視患者報告結局，以評估惡病質試驗中的生活品質改善情況

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依治療類型分類的癌症惡病質市場

  • 醫療設備
  • 營養補充品和膳食補充劑
  • 製藥
    • 阿拉莫林
    • 刺激食慾
    • 皮質類固醇

9. 按分銷管道分類的癌症惡病質市場

  • 醫院藥房
  • 網路藥房
  • 零售藥局

第10章 依給藥途徑分類的癌症惡病質市場

  • 注射
    • 靜脈
    • 皮下
  • 口服

第11章 以最終用戶分類的癌症惡病質市場

  • 門診治療
  • 居家照護
  • 醫院

12. 依患者人口統計特徵分類的癌症惡病質市場

  • 年齡層
    • 成人
    • 老年人
    • 孩子們
  • 性別
    • 女士
    • 男性

第13章 各地區的癌症惡病質市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 癌症惡病質市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國癌症惡病質市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Helsinn Holding SA
    • Qilu Pharmaceutical Co., Ltd.
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Novartis AG
    • Ipsen SA
    • Bristol-Myers Squibb Company
    • Amgen Inc.
    • Astellas Pharma Inc.
    • Johnson & Johnson
Product Code: MRR-02026C4C92B4

The Cancer Cachexia Market is projected to grow by USD 4.10 billion at a CAGR of 7.82% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.24 billion
Estimated Year [2025] USD 2.42 billion
Forecast Year [2032] USD 4.10 billion
CAGR (%) 7.82%

A concise and authoritative framing of cancer cachexia that clarifies clinical complexity, evolving science, and the need for integrated therapeutic and care delivery strategies

Cancer cachexia remains a complex, multifactorial syndrome that undermines patient resilience, complicates oncologic care, and challenges commercial and clinical stakeholders alike. The prevailing clinical imperative is to recognize cachexia early, integrate multidisciplinary management, and align therapeutic strategies with patient-centered outcomes. Recent clinical practice guidelines emphasize the need for coordinated nutritional support, targeted pharmacologic interventions, and symptom-directed care that collectively aim to preserve function and quality of life.

At the same time, research into pathophysiology has clarified contributing mechanisms, including systemic inflammation, metabolic dysregulation, and neurohormonal signaling. These advances have driven renewed interest in developing agents that modulate appetite, counteract catabolism, or intervene in signaling pathways associated with muscle wasting. Consequently, stakeholders from device makers to supplement developers and pharmaceutical sponsors are re-evaluating their roles in an ecosystem that demands integrated solutions across care settings and delivery models.

Therefore, the introduction here sets the stage for understanding how evolving science, shifting care delivery practices, and new commercial imperatives intersect to shape opportunities and risks. With that context, subsequent sections explore transformative landscape shifts, the implications of changing tariff dynamics, actionable segmentation and regional insights, and clear recommendations for industry leaders seeking to move from insight to impact.

Emerging scientific breakthroughs, care pathway redesigns, and digital care delivery are converging to redefine therapeutic development and commercial models for cachexia management

The landscape for cancer cachexia is undergoing transformative shifts driven by converging scientific, clinical, and commercial forces. Advances in basic science have expanded understanding of inflammatory mediators, metabolic reprogramming, and appetite-regulating pathways, which in turn have catalyzed targeted drug development programs and renewed interest in anabolic and appetite-stimulating agents. Concurrently, clinicians are adopting earlier screening and assessment frameworks, shifting the clinical pathway from reactive crisis management to proactive supportive care, and thereby creating demand for products and services that fit earlier intervention windows.

In parallel, technology-enabled care models and telehealth have accelerated, enabling more frequent monitoring of weight, functional capacity, and nutritional intake outside traditional clinic visits. These models facilitate longitudinal data collection and patient engagement, improving the feasibility of multidimensional interventions that combine pharmacotherapy, nutrition, and physical rehabilitation. Moreover, regulators and payers are increasingly receptive to evidence demonstrating functional benefit and patient-reported outcomes, which raises the bar for clinical development while also opening new reimbursement levers for therapies that show meaningful improvement in quality of life.

Commercial dynamics are also shifting. Manufacturers and service providers must adapt to channel diversification as patients and caregivers seek convenient access points for supportive care products and supplements. At the same time, strategic partnerships between pharmaceutical sponsors, nutritional companies, and device manufacturers are emerging to offer bundled solutions that address both biological drivers and supportive needs. Thus, the transformative shifts are not isolated to science or care delivery; they span the full value chain, demanding integrated strategies that align clinical evidence, distribution capabilities, and payer engagement.

Shifts in 2025 tariff policy are reshaping procurement, manufacturing strategies, and payer scrutiny in ways that alter commercial planning for cachexia-related therapies and supplies

The introduction of new tariff policies in 2025 has introduced additional complexity to supply chain and procurement planning for therapies, medical devices, and nutritional products relevant to cancer cachexia. Increased cross-border trade costs raise questions about sourcing strategies, pricing structures, and the resilience of distribution networks. Procurement teams and commercial leaders must weigh the immediate implications for input costs against longer-term decisions about manufacturing localization, contract renegotiations, and inventory strategies that preserve patient access while protecting margins.

Consequently, organizations are examining nearshoring and dual-sourcing approaches to mitigate exposure to tariff volatility, while also reassessing contractual terms with distributors and wholesalers to allocate risk more equitably across the supply chain. In turn, these shifts influence go-to-market tactics, as price-sensitive channels may demand different promotional strategies and support models to maintain uptake. For therapeutics that rely on cold chain logistics or specialized packaging, the incremental tariff burden compounds existing operational complexity and encourages investments in process efficiency and supply chain visibility.

Finally, stakeholders should anticipate that tariff-driven cost pressures will accelerate demand for evidence of economic value and real-world effectiveness. Payers and health systems will scrutinize claims of improved function and reduced resource utilization more closely when acquisition costs rise. Therefore, organizations that proactively adapt procurement, manufacturing, and value demonstration strategies will be better positioned to sustain access and commercial momentum in the face of changing trade policy dynamics.

A multidimensional segmentation framework that aligns treatment modalities, distribution channels, administration routes, care settings, and patient demographics to inform tailored strategies

A nuanced segmentation view reveals where clinical need intersects with delivery modalities and commercial opportunity. Based on treatment type, stakeholders must consider medical devices, nutraceuticals and supplements, and pharmaceuticals, with the pharmaceutical category subdividing into agents such as anamorelin, appetite stimulants, and corticosteroids that address distinct mechanisms and clinical objectives. This continuum requires differentiated evidence strategies: medical devices and supplements often rely on pragmatic, real-world demonstrations of functional benefit and adherence, while pharmaceuticals typically pursue controlled trials to establish efficacy and safety profiles.

Distribution channel segmentation highlights how access pathways shape adoption and patient experience, with hospital pharmacies, online pharmacies, and retail pharmacies each offering different touchpoints for dosing support, counseling, and follow-up. Channel choice influences formulary placement, visibility to prescribers, and the design of patient support programs. Route of administration segmentation underscores clinical and operational trade-offs between injectable and oral therapies, noting that injectables further divide into intravenous and subcutaneous options; injectables may demand facility resources and cold chain logistics, while oral options often emphasize adherence support and convenience for outpatient and home-based care.

End user segmentation across ambulatory care, home care, and hospitals clarifies where interventions must integrate with care teams and workflows. Home care settings increasingly require simplified regimens and robust remote monitoring, whereas hospital-based interventions can leverage multidisciplinary teams and intensive supportive services. Patient demographic segmentation by age group and gender further refines targeting, as adult, geriatric, and pediatric cohorts have unique physiological responses and care considerations, and differences between female and male patients can influence symptom presentation, dosing considerations, and support needs. Taken together, these segments create a multidimensional landscape in which product design, clinical evidence generation, and commercial tactics must align to the specific demands of each therapy-channel-route-user-patient intersection.

Regional considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific drive tailored access, evidence generation, and supply chain resilience strategies for cachexia solutions

Regional dynamics materially affect clinical practice, reimbursement pathways, and supply chain design, and leaders must translate regional patterns into actionable plans. In the Americas, healthcare systems demonstrate a range of payer models and an emphasis on real-world evidence and outcomes that drive reimbursement decisions; this environment favors products backed by demonstrable functional gains and economic value analyses that resonate with integrated delivery networks and private payers. Manufacturers operating here often balance national regulatory expectations with regional differences in procurement and distribution infrastructure.

In Europe, Middle East & Africa, fragmentation across regulatory frameworks and payer systems requires adaptive market access strategies, with local evidence generation and stakeholder engagement playing a pivotal role in uptake. Pricing pressures and budget constraints in parts of Europe emphasize cost-effectiveness and patient benefit, whereas some Middle Eastern and African markets present opportunities for partnership-driven program deployment and capacity building to support therapy delivery. Across this region, tailored approaches to channel partnerships and local manufacturing or sourcing can enhance responsiveness and affordability.

In Asia-Pacific, diverse economic contexts and rapidly evolving healthcare investment are reshaping demand for integrated cachexia solutions. Some markets in the region prioritize rapid adoption of digital health and home-based care models, enabling scalable remote monitoring and patient support programs. Elsewhere, fragmented access and variable reimbursement pathways necessitate focused pilot programs and strong clinical advocacy to demonstrate value. Across all regions, strategic alignment of regulatory strategy, supply chain resilience, and culturally attuned patient engagement will determine which products gain sustainable traction.

Competitive and collaborative dynamics across pharmaceutical, nutritional, device, biotech, and service providers reveal pathways for integrated solutions and partnership-driven scale

Competitive dynamics reflect a mix of established pharmaceutical sponsors, specialty device manufacturers, nutritional companies, and emerging biotechs, each bringing distinct capabilities to the cachexia ecosystem. Pharmaceutical sponsors advance targeted molecules aimed at appetite stimulation, anabolic support, and anti-inflammatory modulation, and they often lead in controlled-evidence development and engagement with regulatory authorities. Nutritional companies and supplement providers complement pharmacologic approaches by focusing on caloric and protein delivery, micronutrient optimization, and adherence-support technologies that can enhance overall therapeutic outcomes.

Device manufacturers contribute dosing platforms, monitoring tools, and supportive technologies that facilitate administration and longitudinal assessment of functional endpoints. Emerging biotechs and clinical-stage developers are also introducing innovative modalities that expand the therapeutic toolkit and may partner with larger organizations to scale development and commercialization. Strategic alliances between these stakeholder groups are common, as combined offerings can address multiple drivers of cachexia and present a more compelling value proposition to clinicians, payers, and patients.

Finally, service providers that specialize in home infusion, nutritional counseling, and remote monitoring play a vital role in adoption by reducing barriers to use and improving adherence. These providers often function as important distribution and support partners, enabling broader access and generating real-world evidence that reinforces clinical value claims. For organizations evaluating competition and potential collaborators, the landscape favors partners who can demonstrate integrated capabilities across evidence generation, delivery logistics, and patient-centric support.

Actionable strategic priorities for leaders to align clinical evidence, supply chain resilience, digital enablement, and cross-sector partnerships to accelerate impact

Industry leaders should pursue targeted investments that align scientific promise with pragmatic delivery models while actively mitigating commercial and operational risk. First, prioritize early identification and engagement of patient cohorts through standardized screening protocols and remote monitoring tools so clinical benefit can be demonstrated earlier and care pathways can be optimized. Parallel to this, design clinical programs that incorporate functional and patient-reported outcomes alongside traditional endpoints to meet payer expectations and to support reimbursement discussions.

Second, build flexible supply chain strategies that include alternative sourcing, nearshoring where appropriate, and collaborations with channel partners to preserve access amid tariff and logistical pressures. Simultaneously, cultivate partnerships that bring together pharmaceuticals, nutrition, and device capabilities into bundled offerings to simplify decision-making for clinicians and payers. Third, invest in digital health and patient support platforms that enhance adherence, capture real-world effectiveness data, and enable value-based contracting conversations. Such investments will also improve patient engagement and long-term outcomes.

Finally, adopt a regionalized go-to-market playbook that adapts evidence generation, pricing, and distribution tactics to local payer requirements and care models. By integrating these approaches-clinical relevance, supply chain resilience, cross-sector partnerships, digital enablement, and regional tailoring-organizations can convert scientific advances into sustainable patient impact and commercial success.

A rigorous mixed-methods research approach combining literature synthesis, stakeholder interviews, case studies, and scenario analysis to support actionable insights

This research synthesizes peer-reviewed clinical literature, regulatory guidance, real-world evidence initiatives, and stakeholder interviews with clinicians, payers, and supply chain experts to develop a comprehensive view of the cachexia ecosystem. Data collection emphasized triangulation across multiple sources to validate trends and to ensure findings reflect both clinical realities and commercial constraints. Qualitative inputs were supplemented by case studies of product launches, distribution models, and evidence-generation strategies to illuminate practical lessons for market entry and scale.

Analytical methods included thematic synthesis of scientific developments, scenario analysis for supply chain and tariff impacts, and segmentation mapping to align therapeutic approaches with channels, routes, care settings, and patient cohorts. Stakeholder interviews probed clinical adoption drivers, reimbursement expectations, and operational barriers, while secondary literature provided context on evolving mechanisms of disease and therapeutic modalities. Throughout, emphasis was placed on transparency of source types and on clearly distinguishing well-established evidence from emerging hypotheses to guide pragmatic decision-making.

A succinct conclusion that underscores the clinical urgency and strategic imperative to integrate evidence, delivery models, and partnerships for durable impact

Cancer cachexia presents both a significant clinical burden and a compelling opportunity for innovative, integrated solutions that combine pharmacologic, nutritional, device, and service elements. The convergence of scientific progress, care delivery transformation, and commercial adaptation creates a window for stakeholders to reimagine therapeutic strategies that prioritize functional outcomes and patient experience. At the same time, policy shifts and tariff dynamics require careful operational planning to preserve access and enable sustainable commercialization.

In conclusion, success in addressing cachexia will rest on the ability of organizations to align rigorous evidence generation with adaptable delivery models, to form strategic collaborations across sectors, and to engage payers with robust demonstrations of functional and economic value. Those who move decisively to integrate clinical, commercial, and operational strategies will be best positioned to deliver measurable benefits to patients and durable returns for investors and partners.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of multimodal nutritional support with exercise protocols to enhance patient outcomes
  • 5.2. Advancements in ghrelin receptor agonist therapies showing improved weight gain efficacy
  • 5.3. Emergence of biomarkers for early detection and monitoring of cancer cachexia progression
  • 5.4. Rising adoption of telemedicine platforms for remote monitoring of cachexia treatment adherence
  • 5.5. Development of combination drug regimens targeting metabolic pathways to counteract muscle wasting
  • 5.6. Increasing investment in personalized medicine approaches to tailor cachexia interventions by patient phenotype
  • 5.7. Integration of machine learning algorithms to predict cachexia onset and optimize therapeutic strategies
  • 5.8. Growing focus on patient-reported outcomes to evaluate quality of life improvements in cachexia trials

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Cachexia Market, by Treatment Type

  • 8.1. Medical Devices
  • 8.2. Nutraceuticals & Supplements
  • 8.3. Pharmaceutical
    • 8.3.1. Anamorelin
    • 8.3.2. Appetite Stimulants
    • 8.3.3. Corticosteroids

9. Cancer Cachexia Market, by Distribution Channel

  • 9.1. Hospital Pharmacies
  • 9.2. Online Pharmacies
  • 9.3. Retail Pharmacies

10. Cancer Cachexia Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Intravenous
    • 10.1.2. Subcutaneous
  • 10.2. Oral

11. Cancer Cachexia Market, by End User

  • 11.1. Ambulatory Care
  • 11.2. Home Care
  • 11.3. Hospitals

12. Cancer Cachexia Market, by Patient Demographics

  • 12.1. Age Group
    • 12.1.1. Adult
    • 12.1.2. Geriatric
    • 12.1.3. Pediatric
  • 12.2. Gender
    • 12.2.1. Female
    • 12.2.2. Male

13. Cancer Cachexia Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cancer Cachexia Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cancer Cachexia Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Helsinn Holding SA
    • 16.3.2. Qilu Pharmaceutical Co., Ltd.
    • 16.3.3. Merck & Co., Inc.
    • 16.3.4. Pfizer Inc.
    • 16.3.5. Novartis AG
    • 16.3.6. Ipsen SA
    • 16.3.7. Bristol-Myers Squibb Company
    • 16.3.8. Amgen Inc.
    • 16.3.9. Astellas Pharma Inc.
    • 16.3.10. Johnson & Johnson

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER CACHEXIA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER CACHEXIA MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER CACHEXIA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER CACHEXIA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CANCER CACHEXIA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CANCER CACHEXIA MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CANCER CACHEXIA MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CANCER CACHEXIA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANCER CACHEXIA MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANCER CACHEXIA MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MEDICAL DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MEDICAL DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MEDICAL DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MEDICAL DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER CACHEXIA MARKET SIZE, BY NUTRACEUTICALS & SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANCER CACHEXIA MARKET SIZE, BY NUTRACEUTICALS & SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER CACHEXIA MARKET SIZE, BY NUTRACEUTICALS & SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANCER CACHEXIA MARKET SIZE, BY NUTRACEUTICALS & SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER CACHEXIA MARKET SIZE, BY NUTRACEUTICALS & SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANCER CACHEXIA MARKET SIZE, BY NUTRACEUTICALS & SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ANAMORELIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ANAMORELIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ANAMORELIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ANAMORELIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ANAMORELIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ANAMORELIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER CACHEXIA MARKET SIZE, BY APPETITE STIMULANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANCER CACHEXIA MARKET SIZE, BY APPETITE STIMULANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER CACHEXIA MARKET SIZE, BY APPETITE STIMULANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANCER CACHEXIA MARKET SIZE, BY APPETITE STIMULANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER CACHEXIA MARKET SIZE, BY APPETITE STIMULANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANCER CACHEXIA MARKET SIZE, BY APPETITE STIMULANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER CACHEXIA MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANCER CACHEXIA MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER CACHEXIA MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANCER CACHEXIA MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER CACHEXIA MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANCER CACHEXIA MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER CACHEXIA MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANCER CACHEXIA MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER CACHEXIA MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANCER CACHEXIA MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER CACHEXIA MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANCER CACHEXIA MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER CACHEXIA MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CANCER CACHEXIA MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER CACHEXIA MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CANCER CACHEXIA MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER CACHEXIA MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CANCER CACHEXIA MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CANCER CACHEXIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GENDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GENDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GENDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GENDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GENDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GENDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANCER CACHEXIA MARKET SIZE, BY FEMALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CANCER CACHEXIA MARKET SIZE, BY FEMALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANCER CACHEXIA MARKET SIZE, BY FEMALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CANCER CACHEXIA MARKET SIZE, BY FEMALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANCER CACHEXIA MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CANCER CACHEXIA MARKET SIZE, BY FEMALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANCER CACHEXIA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CANCER CACHEXIA MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS CANCER CACHEXIA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS CANCER CACHEXIA MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS CANCER CACHEXIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS CANCER CACHEXIA MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE CANCER CACHEXIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE CANCER CACHEXIA MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA CANCER CACHEXIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA CANCER CACHEXIA MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 319. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 320. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 323. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 324. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 325. ASEAN CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. ASEAN CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. ASEAN CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. ASEAN CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. ASEAN CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 330. ASEAN CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 331. ASEAN CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 332. ASEAN CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 333. ASEAN CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 334. ASEAN CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 335. ASEAN CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 336. ASEAN CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 337. ASEAN CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 338. ASEAN CANCER CACHEXIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 339. ASEAN CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 340. ASEAN CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 341. ASEAN CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 342. ASEAN CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 343. ASEAN CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 344. ASEAN CANCER CACHEXIA MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 345. GCC CANCER CACHEXIA